Tranulis, C, Skalli, L, Lalonde, P, Nicole, L, Stip, E. Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature. Drug Safe
2008; 31: 7–20.
Clark, RE, Bartels, SJ, Mellman, TA, Peacock, WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull
2002; 28: 75–84.
Paton, C, Barnes, TRE, Cavanagh, MR, Taylor, D, Lelliott, P. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry
2008; 192: 435–9.
Carnahan, RM, Lund, BC, Perry, PJ, Chrischilles, EA. Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand
2006; 113: 135–41.
Ray, WA, Chung, CP, Murray, KT, Hall, K, Stein, CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med
2009; 360: 225–35.
Baandrup, L, Gasse, C, Jensen, VD, Glenthoj, BY, Nordentoft, M, Lublin, H, et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case–control study. J Clin Psychiatry
2010; 71: 103–8.
Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication (College Report CR138). Royal College of Psychiatrists, 2006.
Nosè, M, Tansella, M, Thornicroft, G, Schene, A, Becker, T, Veronese, A, et al. Is the defined daily dose system a reliable tool for standardising antipsychotic dosages?
Int Clin Psychopharmacol
2008; 23: 287–90.
Biancosino, B, Barbui, C, Marmai, L, Dona, S, Grassi, L. Determinants of antipsychotic polypharmacy in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol
2005; 20: 305–9.
Ito, H, Koyama, A, Higuchi, T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry
2005; 187: 243–7.
Barbui, C, Nosé, M, Mazzi, MA, Thornicroft, G, Schene, A, Becker, T, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol
2006; 21: 355–62.
Tungaraza, TE, Gupta, S, Jones, J, Poole, R, Slegg, G. Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist
2010; 34: 44–6.
Centorrino, F, Goren, JL, Hennen, J, Salvatore, P, Kelleher, JP, Baldessarini, RJ. Multiple versus single antipsychotic agents for hospitalized patients: case control study of risks versus benefits. Am J Psychiatry
2004; 161: 700–6.
Procyshyn, RM, Kennedy, NB, Tse, G, Thompson, B. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry
2001; 46: 334–9.
Kroken, RA, Johnsesn, E, Ruud, T, Wentzel-Larsen, T, J⊘rgensen, HA. Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry
2009; 9: 24 (http://www.biomedcentral.com/content/pdf/1471-244X-9-24.pdf).
Ganguly, R, Kotzan, JA, Miller, LS, Kennedy, K, Martin, BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry
2004; 65: 1377–88.
Centorrino, F, Eakin, M, Bahk, W, Kelleher, JP, Goren, J, Salvatore, P, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry
2002; 159: 1932–3.
Olfson, M, Marcus, SC, Ascher-Svanum, H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull
2007; 33: 1379–87.
Shi, L, Ascher-Svanum, H, Zhu, B, Faries, D, Montgomery, W, Marder, SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv
2007; 58: 482–8.
Citrome, L, Jaffe, A, Levine, J. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Schizophr Res
2010; 119: 153–9.
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry
1988; 45: 789–96.
Karunakaran, K, Tungaraza, TE, Harbone, G. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
2007; 21: 453–6.
Paton, C, Whittington, C, Barnes, TR. Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol
2007; 27: 198–204.
Taylor, DM, Smith, L. Augmentation of clozapine with a second antipsychotic: a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand
2009; 119: 419–25.
Barbui, C, Signoretti, A, Mulè, S, Boso, M, Cipriani, A. Does the addition of a second antipsychotic drug improve clozapine treatment?
2009; 35: 458–68.
Tiihonen, J, Wahlbeck, K, Kiviniemi, V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res
2009; 109: 10–4.
Langan, J, Shajahan, P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist
2010; 34: 58–62.
Sernyak, MJ, Rosenheck, R. Clinicians' reasons for antipsychotic co-prescribing. J Clin Psychiatry
2004; 65: 1597–600.
Gören, JL, Parks, JJ, Ghinassi, FA, Milton, CG, Oldham, JM, Hernandez, P, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf
2008; 34: 571–82.
Lin, CH, Kuo, CC, Chou, LS, Chen, YH, Chen, CC, Huang, KH, et al. A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol
2010; 30: 518–25.
Correll, C, Rummel-Kluge, C, Corves, C, Kane, JM, Leucht, S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull
2009; 35: 443–57.